Summit Therapeutics Stock Down 7.0 %
SMMT stock opened at $4.15 on Tuesday. The company has a market capitalization of $835.48 million, a PE ratio of -5.12 and a beta of -0.97. The stock’s 50 day moving average is $3.19 and its two-hundred day moving average is $1.86. Summit Therapeutics has a 52-week low of $0.66 and a 52-week high of $5.78.
Summit Therapeutics (NASDAQ:SMMT – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.14) EPS for the quarter. Summit Therapeutics had a negative return on equity of 104.32% and a negative net margin of 1,012.41%. The firm had revenue of $5.68 million during the quarter.
Institutional Investors Weigh In On Summit Therapeutics
About Summit Therapeutics
Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
- Get a free copy of the StockNews.com research report on Summit Therapeutics (SMMT)
- 3 Retail Stocks Ringing the Register in 2023
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.